Craig C Hofmeister

List of Publications by Citations

Source: https://exaly.com/author-pdf/9487069/craig-c-hofmeister-publications-by-citations.pdf
Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

232 papers	6,868 citations	38 h-index	80 g-index
244 ext. papers	7,971 ext. citations	3.9 avg, IF	5.03 L-index

#	Paper	IF	Citations
232	Initial genome sequencing and analysis of multiple myeloma. *Nature*, **2011**, 471, 467-72	50.4	1117
231	Lenalidomide after stem-cell transplantation for multiple myeloma. *New England Journal of Medicine*, **2012**, 366, 1770-81	59.2	862
230	The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. *Blood*, **2010**, 116, 2286-94	2.2	595
229	Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. *Blood*, **2014**, 123, 1826-32	2.2	271
228	Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. *Cancer Immunology, Immunotherapy*, **2013**, 62, 1841-9	7.4	216
227	A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. *Blood*, **2012**, 120, 4324-33	2.2	193
226	Ex vivo expansion of umbilical cord blood stem cells for transplantation: growing knowledge from the hematopoietic niche. *Bone Marrow Transplantation*, **2007**, 39, 11-23	4.4	170
225	IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. *Blood*, **2011**, 118, 6387-91	2.2	155
224	Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2017**, 15, 230-269	7.3	142
223	A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma. *Clinical Cancer Research*, **2015**, 21, 4055-61	12.9	126
222	In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. *Journal of Experimental Medicine*, **2013**, 210, 951-68	16.6	95
221	Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. *Lancet Haematology,the*, **2017**, 4, e431-e442	14.6	93
220	Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells. *Clinical Cancer Research*, **2014**, 20, 3989-4000	12.9	90
219	NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2018**, 16, 11-20	7.3	86
218	Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia. *Blood*, **2018**, 131, 855-863	2.2	83
217	Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. *Biology of Blood and Marrow Transplantation*, **2009**, 15, 1422-30	4.7	79
216	Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. *Blood*, **2011**, 118, 535-43	2.2	70

215	Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. *Journal of Clinical Oncology*, **2011**, 29, 3427-34	2.2	69
214	Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation. *Biology of Blood and Marrow Transplantation*, **2008**, 14, 783-9	4.7	63
213	Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. *Blood Cancer Journal*, **2019**, 9, 94	7	59
212	Daratumumab in multiple myeloma. *Cancer*, **2019**, 125, 2364-2382	6.4	58
211	Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. *Blood*, **2016**, 127, 2693-700	2.2	57
210	MicroRNAs activate natural killer cells through Toll-like receptor signaling. *Blood*, **2013**, 121, 4663-71	2.2	56
209	Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. *Journal of Clinical Oncology*, **2020**, 38, 1928-1937	2.2	56
208	Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. *JCI Insight*, **2019**, 5,	9.9	55
207	Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma. *Leukemia and Lymphoma*, **2013**, 54, 1658-64	1.9	54
206	Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. *Nature Communications*, **2019**, 10, 1911	17.4	53
205	Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers. *Journal of Proteomics*, **2016**, 136, 89-98	3.9	52
204	A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma. *Clinical Cancer Research*, **2014**, 20, 5946-55	12.9	52
203	Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2015**, 13, 1398-435	7.3	51
202	Retrospective utility of bronchoscopy after hematopoietic stem cell transplant. *Bone Marrow Transplantation*, **2006**, 38, 693-8	4.4	47
201	Symphony: view-driven software architecture reconstruction		46
200	Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma. *Cancer*, **2001**, 92, 2334-40	6.4	45
199	Circulating miRNA markers show promise as new prognosticators for multiple myeloma. *Leukemia*, **2014**, 28, 1922-6	10.7	44
198	The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo. *PLoS ONE*, **2010**, 5, e10941	3.7	44

197	NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2016**, 14, 389-400	7.3	44
196	Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant. *Journal of Geriatric Oncology*, **2019**, 10, 479-485	3.6	40
195	Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy. *Bone Marrow Transplantation*, **2016**, 51, 1241-4	4.4	39
194	Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma. *British Journal of Cancer*, **2014**, 111, 272-80	8.7	38
193	Ninety-minute daratumumab infusion is safe in multiple myeloma. *Leukemia*, **2018**, 32, 2495-2518	10.7	37
192	Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas. *Biology of Blood and Marrow Transplantation*, **2009**, 15, 547-53	4.7	37
191	A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. *Leukemia and Lymphoma*, **2017**, 58, 2310-2318	1.9	32
190	Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). *Leukemia*, **2020**, 34, 1840-1852	10.7	30
189	Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. *Leukemia*, **2020**, 34, 2430-2440	10.7	30
188	Tocilizumab for steroid refractory acute graft-versus-host disease. *Leukemia and Lymphoma*, **2016**, 57, 81-5	1.9	30
187	Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma. *Molecular Cancer Therapeutics*, **2016**, 15, 830-41	6.1	29
186	Novel gelsolin variant as the cause of nephrotic syndrome and renal amyloidosis in a large kindred. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2014**, 21, 110-2	2.7	29
185	HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide. *Oncotarget*, **2015**, 6, 31134-50	3.3	29
184	Characterization of multiple myeloma vesicles by label-free relative quantitation. *Proteomics*, **2013**, 13, 3013-29	4.8	28
183	Autologous hematopoietic stem cell transplant induces the molecular aging of T-cells in multiple myeloma. *Bone Marrow Transplantation*, **2015**, 50, 1379-81	4.4	27
182	A phase I trial of flavopiridol in relapsed multiple myeloma. *Cancer Chemotherapy and Pharmacology*, **2014**, 73, 249-57	3.5	27
181	Graft-versus-host disease of the skin: life and death on the epidermal edge. *Biology of Blood and Marrow Transplantation*, **2004**, 10, 366-72	4.7	27
180	Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma. *Therapeutic Drug Monitoring*, **2008**, 30, 620-7	3.2	26

179	Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting. *Leukemia*, **2021**, 35, 189-200	10.7	25
178	Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. *OncoImmunology*, **2018**, 7, e1486948	7.2	24
177	Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma. *British Journal of Haematology*, **2018**, 182, 231-244	4.5	23
176	Polymorphism in ANRIL is associated with relapse in patients with multiple myeloma after autologous stem cell transplant. *Molecular Carcinogenesis*, **2017**, 56, 1722-1732	5	22
175	Once-weekly ofatumumab in untreated or relapsed Waldenstrm's macroglobulinaemia: an open-label, single-arm, phase 2 study. *Lancet Haematology,the*, **2017**, 4, e24-e34	14.6	22
174	Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM). *Blood*, **2011**, 118, 302-302	2.2	22
173	Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. *Cancer*, **2019**, 125, 416-423	6.4	22
172	Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104. *Blood*, **2010**, 116, 37-37	2.2	21
171	A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma. *British Journal of Haematology*, **2016**, 174, 323-5	4.5	21
170	Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma. *Molecular Therapy - Oncolytics*, **2017**, 5, 87-96	6.4	20
169	The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma. *Bone Marrow Transplantation*, **2014**, 49, 1323-9	4.4	19
168	The potential of miRNAs as biomarkers for multiple myeloma. *Expert Review of Molecular Diagnostics*, **2014**, 14, 947-59	3.8	19
167	Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 658-668	4.7	17
166	FLT3L and plerixafor combination increases hematopoietic stem cell mobilization and leads to improved transplantation outcome. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 309-13	4.7	17
165	MiR-16 regulates crosstalk in NF-B tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages. *JCI Insight*, **2019**, 4,	9.9	17
164	Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue. *Journal of Pharmaceutical and Biomedical Analysis*, **2014**, 88, 262-8	3.5	16
163	Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma. *British Journal of Haematology*, **2015**, 171, 74-83	4.5	16
162	Central nervous system post-transplant lymphoproliferative disorder despite negative serum and spinal fluid Epstein-Barr virus DNA PCR. *Bone Marrow Transplantation*, **2007**, 39, 249-51	4.4	16

161	Twice-Weekly Oral MLN9708 (Ixazomib Citrate), An Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data. *Blood*, **2013**, 122, 535-535	2.2	16
160	TTP disease course is independent of myeloma treatment and response. *American Journal of Hematology*, **2010**, 85, 304-6	7.1	15
159	How to Integrate Elotuzumab and Daratumumab Into Therapy for Multiple Myeloma. *Journal of Clinical Oncology*, **2016**, 34, 4421-4430	2.2	15
158	Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma. *Leukemia and Lymphoma*, **2010**, 51, 243-51	1.9	14
157	Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study. *Supportive Care in Cancer*, **2014**, 22, 2911-6	3.9	13
156	Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning. *Hematological Oncology*, **2011**, 29, 202-10	1.3	12
155	Clinical utility of autopsy after hematopoietic stem cell transplantation. *Biology of Blood and Marrow Transplantation*, **2007**, 13, 26-30	4.7	12
154	Updated analysis of CALGB/ECOG/BMT CTN 100104: Lenalidomide (Len) vs. placebo (PBO) maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma (MM).. *Journal of Clinical Oncology*, **2015**, 33, 8523-8523	2.2	12
153	Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant. *Leukemia and Lymphoma*, **2015**, 56, 1058-65	1.9	11
152	Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma. *Leukemia Research*, **2008**, 32, 1295-8	2.7	11
151	MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM). *Blood*, **2013**, 122, 1969-1969	2.2	11
150	Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. *Blood*, **2021**, 137, 3604-3615	2.2	11
149	Psychosocial risk predicts high readmission rates for hematopoietic cell transplant recipients. *Bone Marrow Transplantation*, **2018**, 53, 1418-1427	4.4	10
148	A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia,. *Blood*, **2011**, 118, 3701-3701	2.2	10
147	First Interim Results of a Phase I/II Study of Lenalidomide in Combination with Anti-PD-1 Monoclonal Antibody MDV9300 (CT-011) in Patients with Relapsed/Refractory Multiple Myeloma. *Blood*, **2015**, 126, 1838-1838	2.2	10
146	A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005). *Blood*, **2015**, 126, 3036-3036	2.2	10
145	A Phase 1/2 Study of the Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, KPT-8602, in Patients with Relapsed Refractory Multiple Myeloma. *Blood*, **2016**, 128, 4509-4509	2.2	10
144	Unique pattern of renal light chain amyloid deposition with histiocytic transdifferentiation of tubular epithelial cells. *American Journal of Surgical Pathology*, **2012**, 36, 1253-7	6.7	9

143	Phase 2 Study of Carfilzomib (CFZ) with or without Filanesib (FIL) in Patients with Advanced Multiple Myeloma (MM). *Blood*, **2015**, 126, 728-728	2.2	9
142	Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies. *European Journal of Haematology*, **2019**, 102, 494-503	3.8	8
141	Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer. *Medical Oncology*, **2013**, 30, 358	3.7	8
140	Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents. *Hematological Oncology*, **2012**, 30, 156-62	1.3	8
139	Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial. *Blood*, **2019**, 134, 602-602	2.2	8
138	Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM).. *Blood*, **2009**, 114, 431-431	2.2	8
137	Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis. *Blood*, **2012**, 120, 450-450	2.2	8
136	Mucosal protection by cytokines. *Psychophysiology*, **2005**, 4, 446-53		8
135	The effect of statin use at the time of autologous transplant on response and survival in multiple myeloma. *Biology of Blood and Marrow Transplantation*, **2008**, 14, 351-2	4.7	7
134	Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM). *Blood*, **2018**, 132, 1994-1994	2.2	7
133	MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma. *Blood*, **2012**, 120, 727-727	2.2	7
132	Selinexor Demonstrates Marked Synergy with Dexamethasone (Sel-Dex) in Preclinical Models and in Patients with Heavily Pretreated Refractory Multiple Myeloma (MM). *Blood*, **2014**, 124, 4773-4773	2.2	7
131	TG02, an Oral CDK9-Inhibitor, in Combination with Carfilzomib Demonstrated Objective Responses in Carfilzomib Refractory Multiple Myeloma Patients. *Blood*, **2015**, 126, 3052-3052	2.2	7
130	Population pharmacokinetics of lenalidomide in patients with B-cell malignancies. *British Journal of Clinical Pharmacology*, **2019**, 85, 924-934	3.8	6
129	A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma. *Leukemia and Lymphoma*, **2015**, 56, 1043-9	1.9	6
128	Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT). *Biology of Blood and Marrow Transplantation*, **2016**, 22, 71-9	4.7	6
127	Phase 1 Clinical Trial of NPI-0052, a Novel Proteasome Inhibitor in Patients with Multiple Myeloma. *Blood*, **2008**, 112, 2770-2770	2.2	6
126	Phase III Intergroup Study of Lenalidomide (CC-5013) Versus Placebo Maintenance Therapy Following Single Autologous Stem Cell Transplant for Multiple Myeloma (CALGB 100104): Initial Report of Patient Accrual and Adverse Events.. *Blood*, **2009**, 114, 3416-3416	2.2	6

125	BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 1107-1115	4.7	6
124	Pharmacokinetic-Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving High-Dose Melphalan for Autologous Stem Cell Transplant. *CPT: Pharmacometrics and Systems Pharmacology*, **2018**, 7, 748-758	4.5	6
123	Chemotherapeutic agents increase the risk for pulmonary function test abnormalities in patients with multiple myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, **2012**, 12, 325-9	2	5
122	Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial.. *Blood*, **2009**, 114, 132-132	2.2	5
121	Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results. *Blood*, **2011**, 118, 634-634	2.2	5
120	Long-Term Therapy with Lenalidomide in a Patient with POEMS Syndrome. *European Journal of Case Reports in Internal Medicine*, **2014**, 1,	1.2	5
119	A Single Nucleotide Polymorphism in Was Associated With Clinical Response in Multiple Myeloma Patients. *Anticancer Research*, **2019**, 39, 67-72	2.3	5
118	A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies. *Cancer Chemotherapy and Pharmacology*, **2021**, 87, 599-611	3.5	5
117	XRCC1-mediated DNA repair is associated with progression-free survival of multiple myeloma patients after autologous stem cell transplant. *Molecular Carcinogenesis*, **2019**, 58, 2327-2339	5	4
116	Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease. *Clinical Pharmacokinetics*, **2013**, 52, 705-12	6.2	4
115	Phase I adjuvant radiation with docetaxel in high-risk head and neck cancer. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2009**, 32, 396-400	2.7	4
114	Evaluation of pulmonary infiltrates in patients after stem cell transplantation. *Hematology*, **2005**, 10, 469-81	2.2	4
113	Early Evidence of Anti-Lymphoma Activity of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Heavily Pre-Treated Low Grade Lymphoma and Diffuse Large Cell Lymphoma Patients. *Blood*, **2010**, 116, 3966-3966	2.2	4
112	Phase I Study of AR-42 in Relapsed Multiple Myeloma and Lymphoma.. *Blood*, **2012**, 120, 2955-2955	2.2	4
111	The Majority of Myeloma Patients Are Vitamin D Deficient, Unrelated to Survival or Cytogenetics. *Blood*, **2015**, 126, 5336-5336	2.2	4
110	Exploring the Possibility of Using Herpes Simplex Virus in Oncolytic Virotherapy of Multiple Myeloma. *Blood*, **2016**, 128, 4467-4467	2.2	4
109	BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomas. *Bone Marrow Transplantation*, **2019**, 54, 1553-1561	4.4	3
108	Characterizing Pain Experiences: African American Patients With Multiple Myeloma Taking Around-the-Clock Opioids. *Clinical Journal of Oncology Nursing*, **2020**, 24, 538-546	1.1	3

107	Development of a method for clinical pharmacokinetic testing to allow for targeted Melphalan dosing in multiple myeloma patients undergoing autologous transplant. *British Journal of Clinical Pharmacology*, **2020**, 86, 2165-2173	3.8	3
106	Clinical and cost outcomes of pre-emptive plerixafor administration in patients with multiple myeloma undergoing stem cell mobilization. *Leukemia Research*, **2019**, 85, 106215	2.7	3
105	Ixazomib-Lenalidomide-Dexamethasone (IRd) Consolidation Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Large Multi-Center Phase II Trial. *Blood*, **2018**, 132, 123-123	2.2	3
104	Induced Resistance to Bortezomib in Preclinical Model of Waldenstrom Macroglobulinemia Is Associated with Bcl-2 Upregulation.. *Blood*, **2009**, 114, 4919-4919	2.2	3
103	A Phase I Trial Of Anti-KIR Monoclonal Antibody IPH2101 and Lenalidomide For Multiple Myeloma. *Blood*, **2013**, 122, 3181-3181	2.2	3
102	2-Hour Cryotherapy Effectively Reduces Severe Mucositis Associated with High-Dose Melphalan Followed By Stem Cell Rescue: Results from a Randomized Trial. *Blood*, **2014**, 124, 3960-3960	2.2	3
101	Anti-Depressant Use in Patients with Multiple Myeloma Less Common Than Expected. *Blood*, **2016**, 128, 2420-2420	2.2	3
100	A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma. *American Journal of Hematology*, **2021**,	7.1	3
99	Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies. *Blood*, **2017**, 130, 902-902	2.2	3
98	Lenalidomide and Vorinostat Maintenance after Autologous Transplantation in Multiple Myeloma: Long- Term Follow-Up. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 44-49	4.7	3
97	Downregulation of PA28□induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma. *Blood Cancer Journal*, **2020**, 10, 125	7	3
96	Oncolytic herpes simplex virus infects myeloma cells and. *Molecular Therapy - Oncolytics*, **2021**, 20, 519-53	5.1	3
95	Natural history of multiple myeloma patients refractory to venetoclax: A single center experience. *American Journal of Hematology*, **2021**, 96, E68-E71	7.1	3
94	Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma.. *Journal of Clinical Oncology*, **2022**, JCO2102257	2.2	3
93	G-CSF improves safety when you start the day after autologous transplant in multiple myeloma. *Leukemia and Lymphoma*, **2017**, 58, 2947-2951	1.9	2
92	Conflicts of interest, authorship, and disclosures in industry-related scientific publications. *Mayo Clinic Proceedings*, **2010**, 85, 197-9; author reply 201-4	6.4	2
91	Outcomes of Myeloma Patients with t(11;14) Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy. *Blood*, **2018**, 132, 3282-3282	2.2	2
90	Efficacy of Induction Thearapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients. *Blood*, **2018**, 132, 3294-3294	2.2	2

89	Differences in Presentation and Survival Outcomes for African American Patients with Newly Diagnosed Multiple Myeloma. *Blood*, **2018**, 132, 5647-5647	2.2	2
88	The Multiple Myeloma Research Consortium (MMRC) Model: Reduced Time to Trial Activation and Improved Accrual Metrics.. *Blood*, **2010**, 116, 3803-3803	2.2	2
87	Post Autologous Transplant Vorinostat (SAHA) in High Risk Lymphoma: Phase 1 Study of Vorinostat Maintenance. *Blood*, **2012**, 120, 2004-2004	2.2	2
86	T-Cell p16INK4A Expression Increases Post-Transplant in Patients with Multiple Myeloma. *Blood*, **2014**, 124, 2023-2023	2.2	2
85	Geriatric Assessment Metrics Are Associated with Hospital Length of Stay in Pre-Bone Marrow Transplant Myeloma Patients. *Blood*, **2015**, 126, 3200-3200	2.2	2
84	Daratumumab Impairs Myeloma Cell Adhesion Mediated Drug Resistance through CD38 Internalization. *Blood*, **2016**, 128, 4479-4479	2.2	2
83	G-CSF Starting Day +1 after Autologous Transplant Is Safer Than Day +5 or Day +7 in Patients with Multiple Myeloma. *Blood*, **2016**, 128, 5790-5790	2.2	2
82	MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM).. *Journal of Clinical Oncology*, **2013**, 31, 8584-8584	2.2	2
81	Phase I Trial of Lenalidomide and CCI-779 in Patients with Relapsed Multiple Myeloma.. *Blood*, **2009**, 114, 2884-2884	2.2	2
80	Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia. *Blood Cancer Discovery*, **2021**, 2, 600-615	7	2
79	Association of Polymorphism With Overall Survival in Adult Patients With Hematologic Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation. *Anticancer Research*, **2020**, 40, 5707-5713	2.3	1
78	Importin-□and exportin-5 are strong biomarkers of productive reoviral infection of cancer cells. *Annals of Diagnostic Pathology*, **2018**, 32, 28-34	2.2	1
77	Reply to N. Chen et al. *Journal of Clinical Oncology*, **2012**, 30, 341-342	2.2	1
76	Outcomes and Clinical Features of Patients with 1q+ Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone. *Blood*, **2018**, 132, 3241-3241	2.2	1
75	Oncolytics Virus Replication Using Pelareorep (Reolysin) and Carfilzomib in Relapsed Myeloma Patients Increases PD-L1 Expression with Clinical Responses. *Blood*, **2018**, 132, 2655-2655	2.2	1
74	Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy. *Blood*, **2018**, 132, 1884-1884	2.2	1
73	Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple Myeloma. *Blood*, **2019**, 134, 1816-1816	2.2	1
72	Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials. *Blood*, **2019**, 134, 4525-4525	2.2	1

71	IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody, and Lenalidomide Combine to Enhance the Natural Killer (NK) Cell Versus Multiple Myeloma (MM) Effect.. *Blood*, **2009**, 114, 3870-3870	2.2	1
70	Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone In Newly Diagnosed Multiple Myeloma (MM): Final Results of Phase I/II MMRC Trial. *Blood*, **2010**, 116, 1937-1937	2.2	1
69	Phase I Study of Aurora Kinase Inhibitor MLN8237 and Bortezomib in Relapsed or Refractory Multiple Myeloma. *Blood*, **2012**, 120, 1859-1859	2.2	1
68	Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure. *Blood*, **2012**, 120, 4070-4070	2.2	1
67	Differential Distribution of Activated Innate and Adaptive Immune Subsets in G-CSF Mobilized Hematopoietic Stem Cell Allografts May Influence Incidence of Acute (aGVHD) and Chronic Graft-Versus-Host Disease (cGVHD). *Blood*, **2012**, 120, 4192-4192	2.2	1
66	The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and Multiple Myeloma. *Blood*, **2012**, 120, 4286-4286	2.2	1
65	Low Testosterone Levels Are Associated with Shorter Progression Free Survival in Multiple Myeloma. *Blood*, **2012**, 120, 4978-4978	2.2	1
64	Circulating Mir-16 and Mir-25 As New Prognosticators For Multiple Myeloma. *Blood*, **2013**, 122, 1853-1853	2.2	1
63	A Phase 1 Trial Of Reolysin Alone In Patients With Refractory Or Relapsed Multiple Myeloma. *Blood*, **2013**, 122, 3208-3208	2.2	1
62	Reolysin Combined with Carfilzomib for Treatment of Relapsed Multiple Myeloma Patients. *Blood*, **2015**, 126, 1835-1835	2.2	1
61	Population Pharmacokinetic Analysis from First-in-Human Data for HDAC Inhibitor, REC-2282 (AR-42), in Patients with Solid Tumors and Hematologic Malignancies: A Case Study for Evaluating Flat vs. Body Size Normalized Dosing. *European Journal of Drug Metabolism and Pharmacokinetics*, **2021**, 46, 807-816	2.7	1
60	Autopsies Post Hematopoietic Stem Cell Transplant: A Reassessment of Their Role in Patient Management.. *Blood*, **2005**, 106, 1332-1332	2.2	1
59	HDAC Inhibitor AR-42 Decreases CD44 Expression and Sensitizes Myeloma Cells to Lenalidomide. *Blood*, **2014**, 124, 3377-3377	2.2	1
58	Evaluation of Immune Recovery Following Autologous Hematopoietic Cell Transplantation in HIV-Related Lymphoma: Results of the BMT CTN 0803/AMC 071 Trial. *Blood*, **2016**, 128, 1346-1346	2.2	1
57	Immunomodulation of Both Donors and Recipients with Atorvastatin As a Strategy for the Prevention of Acute Graft-Versus-Host Disease (aGVHD): Results of Two Parallel Prospective Trials in Recipients of Matched Sibling Allogeneic Hematopoietic Cell Transplantation (alloHCT). *Blood*, **2012**, 120, 1942-1942	2.2	1
56	A Phase I Trial of the Anti-Inhibitory KIR Antibody, IPH2101, and Lenalidomide in Multiple Myeloma: Interim Results. *Blood*, **2012**, 120, 4058-4058	2.2	1
55	Transplant-associated thrombotic microangiopathy: is the treatment more expensive than the disease?. *Bone Marrow Transplantation*, **2019**, 54, 913-916	4.4	1
54	Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma. *Clinical Cancer Research*, **2021**, 27, 3178-3189	12.9	1

53	Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomas. *Laryngoscope Investigative Otolaryngology*, **2021**, 6, 1008-1019	2.8	1
52	Wavelet analysis of SAECG to identify patients with conduction defects at risk for sudden cardiac death. *Biomedical Sciences Instrumentation*, **1997**, 33, 497-502	0.7	1
51	Safety and Efficacy of Evomela in Myeloma Autotransplants. *Blood*, **2018**, 132, 3446-3446	2.2	0
50	Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life. *Transplantation and Cellular Therapy*, **2021**, 28, 75.e1-75.e1		0
49	Development of a Predictive Pharmacokinetic and Pharmacodynamic Model to Personalize Melphalan Dosing in Autologous Transplant for Patients with Multiple Myeloma. *Blood*, **2014**, 124, 1086-1086	2.2	0
48	Most multiple myeloma patients have low testosterone. *Leukemia and Lymphoma*, **2019**, 60, 836-838	1.9	0
47	A Single Nucleotide Polymorphism (SNP) in the Transporter Gene Is Associated With the Severity of Oral Mucositis in Multiple Myeloma Patients Receiving Autologous Stem Cell Transplant Followed by Melphalan Therapy.. *Anticancer Research*, **2022**, 42, 385-395	2.3	0
46	Registering a CD38 antibody upfront for multiple myeloma. *Lancet, The*, **2019**, 394, 3-4	40	
45	High-risk myeloma: when to transplant-or not. *Seminars in Oncology*, **2014**, 41, e1-9	5.5	
44	Wavelet Analysis of High-Resolution Signal-Averaged Electrocardiograms in Postinfarction Patients with Bundle Branch Block. *Cardiovascular Engineering (Dordrecht, Netherlands)*, **2002**, 2, 33-35		
43	Chromatin Accessibility Identifies Regulatory Elements Predictive of Oncogene Expression in Multiple Myeloma. *Blood*, **2020**, 136, 31-32	2.2	
42	Role of clonoSEQ , a Next-Generation Sequencing (NGS) Assay and PET/CT As a Measure of Minimal Residual Disease Negativity Among Patients with Multiple Myeloma. *Blood*, **2020**, 136, 50-51	2.2	
41	Renal Cell Cancer **2006**, 789-812		
40	Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients. *Blood*, **2021**, 138, 1616-1616	2.2	
39	BRAF Mutations and Inflammatory Gene Expression in Myeloma Cells from Patients with Renal Dysfunction. *Blood*, **2021**, 138, 1624-1624	2.2	
38	Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR). *Blood*, **2021**, 138, 2758-2758	2.2	
37	Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies. *Blood*, **2021**, 138, 3134-3134	2.2	
36	The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Patients with Multiple Myeloma.. *Blood*, **2007**, 110, 5129-5129	2.2	

35	Impact of Early Progression on Long Term Outcomes Among Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy. *Blood*, **2018**, 132, 3302-3302	2.2
34	The Impact of a Physical Activity Intervention Can be Accurately Assessed By Smart Watches in Patients Completing Autologous Stem Cell Transplantation for Lymphoma or Multiple Myeloma: Results of a Feasibility Study. *Blood*, **2018**, 132, 5911-5911	2.2
33	The Role of Proteasome Activator PA28 in Multiple Myeloma. *Blood*, **2019**, 134, 5499-5499	2.2
32	Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR). *Blood*, **2019**, 134, 3188-3188	2.2
31	Allograft T-Cell, T-Regs, NK-Cell and B-Cell Content Influence Distinct Clinical Outcomes Following G-CSF Mobilized Hematopoietic Stem Cell Transplantation. *Blood*, **2014**, 124, 2494-2494	2.2
30	Phase II Trial Evaluating the Safety and Efficacy of Atorvastatin for the Prophylaxis of Acute Graft Vs. Host Disease (aGVHD) in Patients with Hematological Malignancies Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT). *Blood*, **2014**, 124, 3929-3929	2.2
29	Impact of Atorvastatin on Cellular Immunome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT). *Blood*, **2014**, 124, 1166-1166	2.2
28	Proteomic Characterization of Circulating Extracellular Vesicles Identifies Novel Serum Myeloma Associated Markers. *Blood*, **2015**, 126, 1814-1814	2.2
27	The Majority of Myeloma Patients Are Hypogonadal but This Is Not Associated with High Risk Cytogenetics. *Blood*, **2015**, 126, 5329-5329	2.2
26	Small RNA Deep Sequencing Highlights the Important Contribution of Mirnas in Regulating IRF4/c-Myc Axis in Myeloma Development. *Blood*, **2015**, 126, 1791-1791	2.2
25	Comparison of Two Doses of Antithymocyte Globulin (ATG) in Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT). *Blood*, **2015**, 126, 4328-4328	2.2
24	Relative Clone Size By FISH of Both Del(13q) and Del(17p) Independently Impact Overall Survival. *Blood*, **2016**, 128, 4444-4444	2.2
23	Cytomegalovirus Reactivation Does Not Increase Subsequent Risk for Acute Graft-Versus-Host Disease, Malignant Disease Relapse, or Infection Following Allogeneic Hematopoietic Cell Transplantation. *Blood*, **2016**, 128, 3409-3409	2.2
22	Psychosocial Risk Is Associated with High Readmission Rates and Increased Length of Stay for Patients Following Hematopoietic Stem Cell Transplantation. *Blood*, **2016**, 128, 1241-1241	2.2
21	Early Infection Attenuates Hematologic Malignant Disease Relapse Following Initial Allogeneic Hematopoietic Cell Transplantation. *Blood*, **2016**, 128, 3410-3410	2.2
20	Hospital Care of Pathological Vertebral Fracture (PVF) in Multiple Myeloma (MM) Patients: Burden of Illness and Patterns of Care. *Blood*, **2008**, 112, 2409-2409	2.2
19	Attainment of Minimal Residual Disease Negative State Is Crucial for Successful Outcome of Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in Advanced Chronic Lymphocytic Leukemia (CLL).. *Blood*, **2008**, 112, 2170-2170	2.2
18	Allogeneic Stem Cell Transplantation for Patients with Chemo-Refractory or Progressive Aggressive Non-Hodgkin Lymphomas.. *Blood*, **2008**, 112, 3265-3265	2.2

17	Characterization of Early Natural Killer Cell Reconstitution Following Autologous Transplantation in Multiple Myeloma.. *Blood*, **2009**, 114, 4641-4641	2.2
16	p53-Inducible Microrna 192 and 215 Regulate p53 Expression and IGF1 Axis in Multiple Myeloma.. *Blood*, **2009**, 114, 1973-1973	2.2
15	Novel Monoclonal Antibody Enhances Natural Killer (NK) Cell Cytotoxicity against Multiple Myeloma (MM): Interim Phase 1 Trial Results.. *Blood*, **2009**, 114, 2880-2880	2.2
14	Analysis of 179 Patients with Newly Diagnosed Multiple Myeloma (MM) Treated with Novel Agents Followed by Autologous Stem Cell Transplantation (ASCT): a Retrospective Study. *Blood*, **2010**, 116, 1343-1343	2.2
13	IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody for Multiple Myeloma: Interm Phase 1 Trial Results and Correlative Biologic and Safety Data. *Blood*, **2010**, 116, 1966-1966	2.2
12	Early Versus Delayed Autologous Stem Cell Transplant In Patients Receiving Novel Therapies for Multiple Myeloma. *Blood*, **2010**, 116, 3564-3564	2.2
11	Phase I Trial of Flavopiridol In Relapsed Myeloma: Brief Response In t(4;14) with Significant Neutropenia. *Blood*, **2010**, 116, 1933-1933	2.2
10	Tablet-Based Assessment of Fatigue, Depression, and Pain In Myeloma Patients: Cohort Study of Inflammatory Cytokines and QOL Measures In the Newly Diagnosed, Patients on Lenalidomide, and Survivors.. *Blood*, **2010**, 116, 3807-3807	2.2
9	The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development. *Blood*, **2011**, 118, 1024-1024	2.2
8	Immune Reconstitution and Quality of Life Analyses After Autologous Transplant for Multiple Myeloma. *Blood*, **2012**, 120, 4460-4460	2.2
7	miRNA in Serum and Bone Marrow Plasma Cells From Multiple Myeloma Patients.. *Blood*, **2012**, 120, 2921-2921	2.2
6	Immune Reconstitution At Days 30 and 100 Following Allogeneic Stem Cell Transplant and Association with Subsequent Development of Chronic Graft-Versus-Host Disease. *Blood*, **2012**, 120, 1949-1949	2.2
5	Phase I Trial of Lenalidomide + Vorinostat After Autologous Transplant in Multiple Myeloma.. *Blood* , **2012**, 120, 3114-3114	2.2
4	FLT3L and AMD3100 Combination Increases Hematopoietic Stem Cell Mobilization and Leads To Improved Transplantation Outcome. *Blood*, **2013**, 122, 901-901	2.2
3	Efficacy and Safety Of Pomalidomide Plus Low-Dose Dexamethasone In Advanced Multiple Myeloma: Results Of Randomized Phase 2 and 3 Trials (MM-002/MM-003). *Blood*, **2013**, 122, 3185-3185	2.2
2	Understanding The Differential Response Of Multiple Myeloma To Reovirus Treatment. *Blood*, **2013** , 122, 3232-3232	2.2
1	Improved Treatment Related Mortality in Patients with Primary Systemic Amyloidosis (AL Amyloidosis) undergoing Autologous Hematopoietic Stem Cell Transplant (aHSCT). **2019**, 2, 12-18	